US supports use of Novavax vaccine against COVID-19 in adults

Share your love

The United States Centers for Disease Control (CDC) endorsed on Tuesday (07.19.2022) the use in adults of the Novavax vaccine against COVID-19, the fourth serum of this type in be approved in the country.

“Today we take another step forward in our nation’s fight against the virus. Novavax’s protein-based adult vaccine has been licensed, and we now have four safe and effective sera available to all Americans,” the president said in a statement. Joe Biden.

Hours earlier, the director of the CDC, Rochelle P. Walensky, had announced that the Novavax vaccine is “safe and effective” and encouraged those people who have been waiting to be vaccinated with a serum that uses technology to get it. different from those available up to now.

“With COVID-19 cases on the rise in various parts of the country, vaccination is crucial to help protect against the complications of severe COVID-19 illness,” Walensky said.

Novavax’s vaccine will be available for injection in US hospitals and pharmacies within weeks. The whey contains the spike protein of the SARS-CoV-2 virus and an adjuvant, which is a substance that helps strengthen the immune response to an antigen.

In the case of Novavax, the Matrix-M adjuvant has been used, which has saponin extracts from the bark of the Soapbark tree, which is native to Chile.

To evaluate the vaccine, a clinical trial was carried out in the US and Mexico before the appearance of the delta and omicron variants and in which the serum demonstrated an efficacy of 90.4% in preventing COVID- 19.

Read Also   Suspicions and mystery surround the sudden deaths of six Cuban generals

That trial involved 17,200 volunteers who received the vaccine and 8,300 who were given a saline placebo.

The US authorities are calling on citizens to get vaccinated and receive booster doses, given a rebound in cases due to the expansion of the BA.4 and BA.5 omicron subvariants.

Share your love

Leave a Reply

Your email address will not be published.